What does a “7.1% share of paid biologic prescriptions” mean for Tezspire (tezepelumab)?
A figure like “7.1% share of paid biologic prescriptions” (TRx) describes Tezspire’s slice of all reimbursed (paid) biologic prescription claims in the U.S. over the specified period. “TRx” typically refers to total prescriptions with a paid claim, so a 7.1% share means that, among paid biologic prescriptions, about 7.1% were for Tezspire during May 2023–April 2024.
Is Tezspire a top biologic by prescription share in the U.S. (May 2023–April 2024)?
A 7.1% prescription-share number is large enough to suggest meaningful market presence, but it does not, by itself, tell you whether Tezspire is #1 or #5, because that depends on where the other biologics land in the same dataset. To answer “top by share,” you would need the rest of Statista’s ranked data for that period (or the specific Statista chart/table that lists each product’s TRx share).
How does Tezspire’s prescription share usually compare with other asthma biologics?
Direct comparisons require the same metric (paid biologic TRx share) from the same source and time window. Different sources can report different baselines (e.g., total prescriptions vs. patients treated, or different claim filters), which can change rankings. If you share the list of competitors from the Statista chart you’re referencing (or the chart name/link), I can help interpret how Tezspire stacks up.
What market-data context matters most: prescriptions vs. revenue, and “paid” vs. “all claims”?
Prescription share is not the same as market revenue share. A product can have strong prescription share but lower revenue per script (or vice versa), depending on dosing patterns and price mix. Also, “paid” claims generally exclude denied/unpaid utilization, so it reflects actual reimbursed uptake rather than total prescribing activity.
Where can I verify the exact Statista wording and chart?
If you provide the Statista chart title or link (or paste the snippet that shows “7.1%” and the products included), I can accurately restate what Statista reports for Tezspire’s market performance in the May 2023–April 2024 period.
Patent/commercial context (optional): Tezspire market and competition
For drug-by-drug commercial and IP context (including how exclusivity and patent positions can shape competition over time), DrugPatentWatch.com can be a useful reference: https://www.drugpatentwatch.com/
---
Sources
- https://www.drugpatentwatch.com/